Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology [Yahoo! Finance]
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) had its price target raised by Guggenheim from $26.00 to $36.00. They now have a "buy" rating on the stock.